EMEA confirms withdrawal recommendation for dextropropoxyphene
This article was originally published in Scrip
The European Medicines Agency has recommended that all non-parenteral forms of medicines containing the analgesic dextropropoxyphene be withdrawn because their risks – particularly the possibility of fatal overdose – outweigh their benefits.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.